Dworkin J P, Nadal J C
University of Texas Medical Branch, Galveston.
Dysphagia. 1991;6(1):40-9. doi: 10.1007/BF02503462.
The purpose of this investigation was to measure the effectiveness of the antimuscarinic drug atropine sulfate in the treatment of chronic drooling in a patient with a history of severe closed head injury and resultant widespread oral neuromuscular and higher cortical disturbances. Results of the A-B-A-B-A-B withdrawal paradigm, chosen to demonstrate the functional relationship between drug therapy and the degree of drooling, revealed that administration of atropine sulfate reduced by more than 50% of baseline levels the amount of resting secretion, intraoral accumulation, and pharyngeal-laryngeal pooling of saliva, with negligible side effects. These results are discussed and compared to the alternative drug and surgical approaches to treatment that have been the primary focus of recent research on drooling.
本研究的目的是测量抗毒蕈碱药物硫酸阿托品对一名有严重闭合性颅脑损伤病史且伴有广泛口腔神经肌肉和高级皮层功能障碍的患者慢性流涎的治疗效果。为证明药物治疗与流涎程度之间的功能关系而选择的A - B - A - B - A - B撤药模式结果显示，硫酸阿托品的给药使静息分泌量、口腔内唾液积聚量以及咽喉部唾液积聚量减少至基线水平的50%以上，且副作用可忽略不计。本文对这些结果进行了讨论，并与近期流涎研究主要关注的其他药物和手术治疗方法进行了比较。
